Mycobacterium Bovis Vascular Graft Infection Following BCG Immunotherapy with Prolonged Latency
Document Type
Conference Proceeding - Restricted Access
Publication Date
5-9-2025
Abstract
The Mycobacterium species is characterized as the leading cause of infection-related death globally. While there has been considerable clinical and research spotlight on M. tuberculosis, the counterpart strain Mycobacterium bovis has been used in the development of the live attenuated Bacillus Calmette-Guerin (BCG) vaccine. This vaccine is a remarkable immunotherapy for non-muscle-invasive bladder cancer. Although adverse effects following the BCG immunotherapy are rare, M. bovis-related infections transpiring in the genitourinary, cerebral, and vascular systems have been described. Among vascular cases, none report a time gap greater than 10 years between receiving the BCG immunotherapy and presentation of M. bovis infection. We present a case of vascular graft infection secondary to M. bovis following BCG injections 18 years prior for treatment of bladder cancer.
Recommended Citation
Khan A, Emery R. Mycobacterium bovis vascular graft infection following BCG immunotherapy with prolonged latency. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1769